Printer Friendly

SMITHKLINE BEECHAM AND DERMIK LABORATORIES SIGN CO-MARKETING AGREEMENT FOR BACTROBAN

 SMITHKLINE BEECHAM AND DERMIK LABORATORIES SIGN
 CO-MARKETING AGREEMENT FOR BACTROBAN
 PHILADELPHIA, Nov. 4 /PRNewswire/ -- SmithKline Beecham (NYSE: SBH) and Dermik Laboratories, a subsidiary of Rhone-Poulenc Rorer Inc. (NYSE: RPR), announced an agreement to co-promote SmithKline Beecham's Bactroban, a topical antibiotic ointment, to dermatologists in the U.S.
 Bactroban (mupirocin) is the first topical product with specific activity against organisms such as Staphylococcus and Streptococcus which frequently cause skin infections. Bactroban is indicated for the treatment of impetigo, a contagious skin infection most commonly seen in children.
 "There are clear benefits for both companies," said Argeris Karabelas, Ph.D., senior vice president, U.S. marketing, SmithKline Beecham Pharmaceuticals. "Through Dermik's strong franchise with dermatologists, SmithKline Beecham's Bactroban gains significantly broader exposure to this important physician group which establishes the benchmark for topical medications in treatment of skin disorders."
 "Dermik is pleased with this agreement and for the opportunity to contribute to the growth of a highly successful product which complements our dermatological line," said Thomas Bigger, general manager and vice president of RPR Dermatologicals.
 SmithKline Beecham will continue to actively promote Bactroban to other physicians including general practitioners and pediatricians.
 SmithKline Beecham -- one of the world's leading health care companies -- discovers, develops, manufactures and markets human and animal pharmaceuticals, over-the-counter medicines and clinical laboratory testing services.
 Dermik Laboratories, which is dedicated to dermatology, develops and markets both prescription and OTC pharmaceuticals for treatment of skin- related disorders.
 /delval/
 -0- 11/4/92
 /CONTACT: Sharyn M. Arnold of SmithKline Beecham, 215-751-7074, or Bob Pearson of Dermik Laboratories, 215-454-3872/
 (SBH RPR) CO: SmithKline Beecham; Dermik Laboratories; Rhone-Poulenc Rorer Inc. ST: Pennsylvania IN: MTC SU:


MK -- PH011 -- 2375 11/04/92 10:09 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 4, 1992
Words:280
Previous Article:NGSA ANTICIPATES PRODUCTIVE RELATIONSHIP WITH PRESIDENT-ELECT CLINTON
Next Article:IVAX COMPLETES ACQUISITION OF CERTAIN ASSETS OF THE U.K. GENERIC PHARMACEUTICAL OPERATIONS OF MEDEVA PLC
Topics:


Related Articles
MICHIGAN DEPARTMENT OF PUBLIC HEALTH AND SMITHKLINE BEECHAM ANNOUNCE VACCINE COLLABORATION
PASTEUR MERIEUX SERUMS ET VACCINS AND SMITHKLINE BEECHAM ANNOUNCE VACCINE AGREEMENT
SIGMA-TAU, SMITHKLINE BEECHAM ANNOUNCE AGREEMENT FOR CO-PROMOTION OF ALCAR IN UNITED STATES
CAMBRIDGE BIOTECH CORPORATION AND SMITHKLINE BEECHAM SIGN VACCINE ALLIANCE
ADRIA LABORATORIES AND SMITHKLINE BEECHAM AGREE TO CO-PROMOTE MYCOBUTIN
ADRIA ANNOUNCES FINALIZATION OF MYCOBUTIN CO-PROMOTION AGREEMENT
ABBOTT AND SMITHKLINE BEECHAM SIGN MARKETING AND DISTRIBUTION AGREEMENT
SMITHKLINE BEECHAM AND EDS ANNOUNCE A JOINT MARKETING AGREEMENT
SMITHKLINE BEECHAM AND TAKEDA COMPLETE GENOMICS AGREEMENT; TWO COMPANIES TO COLLABORATE IN BOTH RESEARCH AND MARKETING
SmithKline Beecham Clinical Laboratories and United HealthCare Announce Preferred Laboratory Provider Agreement

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters